News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,413 Results
Type
Article (44745)
Company Profile (720)
Press Release (680939)
Multimedia
Podcasts (140)
Webinars (25)
Section
Business (211347)
Career Advice (2695)
Deals (37060)
Drug Delivery (127)
Drug Development (82410)
Employer Resources (179)
FDA (16494)
Job Trends (15837)
News (355812)
Policy (32662)
Tag
Academia (2163)
Academic (2)
Accelerated approval (18)
Adcomms (27)
Allergies (130)
Alliances (51987)
ALS (145)
Alzheimer's disease (1616)
Antibody-drug conjugate (ADC) (257)
Approvals (16568)
Artificial intelligence (459)
Autoimmune disease (108)
Automation (28)
Bankruptcy (384)
Best Places to Work (11769)
BIOSECURE Act (23)
Biosimilars (157)
Biotechnology (443)
Bladder cancer (132)
Brain cancer (47)
Breast cancer (507)
Cancer (4059)
Cardiovascular disease (364)
Career advice (2278)
Career pathing (38)
CAR-T (242)
CDC (36)
Cell therapy (674)
Cervical cancer (32)
Clinical research (69272)
Collaboration (1430)
Company closure (4)
Compensation (959)
Complete response letters (62)
COVID-19 (2694)
CRISPR (82)
C-suite (623)
Cystic fibrosis (139)
Data (5015)
Decentralized trials (2)
Denatured (42)
Depression (108)
Diabetes (450)
Diagnostics (6797)
Digital health (36)
Diversity (8)
Diversity, equity & inclusion (43)
Drug discovery (212)
Drug pricing (180)
Drug shortages (34)
Duchenne muscular dystrophy (203)
Earnings (90567)
Editorial (54)
Employer branding (24)
Employer resources (157)
Events (120827)
Executive appointments (981)
FDA (19012)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (5)
Frontotemporal dementia (17)
Funding (1263)
Gene editing (179)
Generative AI (43)
Gene therapy (551)
GLP-1 (1017)
Government (4135)
Grass and pollen (8)
Guidances (370)
Healthcare (18426)
HIV (47)
Huntington's disease (40)
IgA nephropathy (74)
Immunology and inflammation (252)
Immuno-oncology (21)
Indications (61)
Infectious disease (2930)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (97)
Intellectual property (200)
Interviews (522)
IPO (17423)
IRA (53)
Job creations (4485)
Job search strategy (1866)
Kidney cancer (15)
Labor market (73)
Layoffs (630)
Leadership (35)
Legal (8217)
Liver cancer (87)
Longevity (12)
Lung cancer (577)
Lymphoma (278)
Machine learning (31)
Management (62)
Manufacturing (645)
MASH (149)
Medical device (14291)
Medtech (14320)
Mergers & acquisitions (20553)
Metabolic disorders (1177)
Multiple sclerosis (138)
NASH (20)
Neurodegenerative disease (229)
Neuropsychiatric disorders (60)
Neuroscience (2658)
NextGen: Class of 2025 (6774)
Non-profit (3786)
Now hiring (60)
Obesity (573)
Opinion (307)
Ovarian cancer (144)
Pain (167)
Pancreatic cancer (181)
Parkinson's disease (235)
Partnered (29)
Patents (428)
Patient recruitment (341)
Peanut (57)
People (60892)
Pharmaceutical (134)
Pharmacy benefit managers (26)
Phase I (21570)
Phase II (30576)
Phase III (23013)
Pipeline (3046)
Policy (271)
Postmarket research (2432)
Preclinical (9086)
Press Release (66)
Prostate cancer (200)
Psychedelics (48)
Radiopharmaceuticals (276)
Rare diseases (688)
Real estate (6201)
Recruiting (75)
Regulatory (23861)
Reports (44)
Research institute (2079)
Resumes & cover letters (418)
Rett syndrome (17)
RNA editing (15)
RSV (71)
Schizophrenia (137)
Series A (215)
Series B (159)
Service/supplier (27)
Sickle cell disease (82)
Special edition (24)
Spinal muscular atrophy (153)
Sponsored (37)
Startups (3990)
State (2)
Stomach cancer (17)
Supply chain (100)
Tariffs (93)
The Weekly (96)
Vaccines (970)
Venture capital (68)
Weight loss (402)
Women's health (55)
Worklife (21)
Date
Today (282)
Last 7 days (1251)
Last 30 days (3468)
Last 365 days (32039)
2025 (27864)
2024 (36742)
2023 (41461)
2022 (52107)
2021 (56089)
2020 (54104)
2019 (46689)
2018 (35531)
2017 (34218)
2016 (33344)
2015 (38983)
2014 (32405)
2013 (27736)
2012 (29038)
2011 (29045)
2010 (27057)
Location
Africa (869)
Alabama (80)
Alaska (6)
Arizona (232)
Arkansas (12)
Asia (43677)
Australia (7223)
California (9958)
Canada (2922)
China (943)
Colorado (413)
Connecticut (439)
Delaware (286)
Europe (97396)
Florida (1436)
Georgia (314)
Hawaii (3)
Idaho (61)
Illinois (737)
India (55)
Indiana (486)
Iowa (20)
Japan (333)
Kansas (119)
Kentucky (35)
Louisiana (24)
Maine (76)
Maryland (1216)
Massachusetts (7414)
Michigan (313)
Minnesota (575)
Mississippi (4)
Missouri (121)
Montana (32)
Nebraska (23)
Nevada (106)
New Hampshire (78)
New Jersey (2747)
New Mexico (31)
New York (2634)
North Carolina (1412)
North Dakota (10)
Northern California (4665)
Ohio (294)
Oklahoma (22)
Oregon (47)
Pennsylvania (2045)
Puerto Rico (20)
Rhode Island (46)
South America (1246)
South Carolina (51)
South Dakota (1)
Southern California (3767)
Tennessee (145)
Texas (1499)
United States (35892)
Utah (285)
Virginia (246)
Washington D.C. (79)
Washington State (834)
West Virginia (4)
Wisconsin (98)
Wyoming (2)
726,413 Results for "eli lilly and company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
Drug pricing
White House Strikes GLP-1 Pricing Deal With Lilly, Novo
The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.
November 6, 2025
·
3 min read
·
Annalee Armstrong
Gene therapy
Lilly Doubles Down on Eye Diseases, Adding to BD Spree
MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.
November 10, 2025
·
1 min read
·
Annalee Armstrong
Earnings
Lilly Walks Pricing Tightrope With Upcoming Weight Loss Pill Orforglipron
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs to pay for the next generation of obesity medicines to come after that.
October 30, 2025
·
4 min read
·
Annalee Armstrong
Artificial intelligence
J&J, Lilly Crest AI Wave With Nvidia Partnerships
Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to create the industry’s ‘most powerful supercomputer’ and J&J building a virtual operating room.
October 29, 2025
·
2 min read
·
Tristan Manalac
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.
November 10, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.
October 30, 2025
·
2 min read
·
Tristan Manalac
Pain
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program
Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly said that results were not sufficient for advancement of the Asahi Kasei–partnered asset.
October 31, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s
In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.
September 17, 2025
·
3 min read
·
Annalee Armstrong
1 of 72,642
Next
